QT Vascular on why it chose to list in Singapore
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
QT Vascular, a company producing devices to treat diseased arteries in the heart and elsewhere, aims to develop new products and enhance its existing ones, and so is planning a listing on the Singapore Exchange (SGX) to fund its efforts.
The company, which operates out of California and Singapore, registered revenue of US$1,452,000 for FY2012; in FY2013 that ended Sept 30, revenue doubled to US$3,004,000.
Besides developing new products, the company plans to use the IPO proceeds for commercial expansion and for general working capital purposes.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Singaporeans can now buy record amount of yen per Singdollar
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
StarHub hands Ensign InfoSecurity control back to Temasek in S$115 million deal, books S$200 million gain
